From Adjuvant to Metastatic in Melanoma This program will include a discussion of offlabel treatment and investigational agents not approved by the FDA for use in the US and data that were presented in abstract form ID: 763055
Download Presentation The PPT/PDF document "From Adjuvant to Metastatic in Melanoma..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
From Adjuvant to Metastatic in Melanoma
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.
Immune Checkpoint Inhibition
The Metastatic SettingDosing
CheckMate-0674-Year Survival Data by PD-L1 Expression
CheckMate-0674-Year Survival Data
Brain Metastases CheckMate 204
Brain MetastasesAustralian ABC Trial
Brain MetastasesImplications for Practice
Duration of Therapy
Duration of Therapy (cont)
Duration of TherapyImplications for Practice
The Adjuvant SettingKEYNOTE-054
The Adjuvant SettingCheckMate-238
Considerations in the Adjuvant Setting
Considerations in the Adjuvant Setting (cont)
Treating Patients With BRAF-Positive Disease
Emerging Approaches
Thoughts on When Trials of Investigational Drugs Should Progress to Phase 3
Emerging Approaches (cont)
irAEs
Working Together as a Team
Guidelines for Identifying and Managing irAEs
Communication
Case ExampleA Patient With Colitis
Concluding Remarks
Abbreviations
Abbreviations (cont)